{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T16:10:12Z","timestamp":1727539812704},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[1994,8,1]],"date-time":"1994-08-01T00:00:00Z","timestamp":775699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1994,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>No satisfactory medical therapy exists for the treatment of primary hyperparathyroidism. Calcitonin and diphosphonates do not give good long-term control. This work examines the efficacy of the somatostatin analogue octreotide in the management of hyperparathyroidism. Twenty-one patients were admitted before parathyroid surgery and were treated for 6 days with subcutaneous octreotide 100 \u03bcg twice daily. Fasting blood samples were taken for determination of serum levels of calcium and parathyroid hormone, and 24-h urinary calcium excretion was measured before and after treatment. A significant decrease in urinary calcium was demonstrated, but the reduction in serum calcium level was not statistically significant and there was no change in serum parathyroid hormone concentration. Octreotide may provide therapy for patients with hyperparathyroidism and for those who have undergone unsuccessful neck exploration or who are unfit for operation. It may ameliorate hypercalciuria and reduce stone formation. The octapeptide may also have a potential role as a diagnostic test in primary hyperparathyroidism by determining the symptomatic effect of reducing raised levels of serum and urinary calcium.<\/jats:p>","DOI":"10.1002\/bjs.1800810819","type":"journal-article","created":{"date-parts":[[2007,3,3]],"date-time":"2007-03-03T21:03:15Z","timestamp":1172955795000},"page":"1141-1143","source":"Crossref","is-referenced-by-count":9,"title":["Somatostatin and primary hyperparathyroidism"],"prefix":"10.1093","volume":"81","author":[{"given":"M E","family":"Lucarotti","sequence":"first","affiliation":[{"name":"University Department of Surgery, Bristol Royal Infirmary , Marlborough Street, Bristol BS2 8HW,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Hamilton","sequence":"additional","affiliation":[{"name":"University Department of Surgery, Bristol Royal Infirmary , Marlborough Street, Bristol BS2 8HW,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J R","family":"Farndon","sequence":"additional","affiliation":[{"name":"University Department of Surgery, Bristol Royal Infirmary , Marlborough Street, Bristol BS2 8HW,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1994,8,1]]},"reference":[{"key":"2024092815371502500_bib1","first-page":"46","volume-title":"The Parathyroid Glands and Metabolic Bone Disease. Selected Studies","author":"Albright","year":"1948"},{"key":"2024092815371502500_bib2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1001\/archinte.141.13.1761","article-title":"Primary hyperparathyroidism. Changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests","volume":"141","author":"Lafferty","year":"1981","journal-title":"Arch Intern Med"},{"key":"2024092815371502500_bib3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(80)91783-3","article-title":"Primary hyperparathyroidism: changes in the pattern of clinical presentation","volume":"i","author":"Mundy","year":"1980","journal-title":"Lancet"},{"key":"2024092815371502500_bib4","first-page":"17","article-title":"Treatment of acromegaly with Sandostatin","volume":"11","author":"Liuzzi","year":"1990","journal-title":"Aktuelle Endokrinologie und Stoffwechsel"},{"key":"2024092815371502500_bib5","first-page":"9","article-title":"Treatment of neuroendocrine tumors with a somatostatin analogue (Sandostatin)","volume":"97","author":"Somlo","year":"1990","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"2024092815371502500_bib6","first-page":"120","article-title":"Acid inhibitory effects of somatostatin analog in malignant gastrinomas","volume":"12","author":"Koop","year":"1990","journal-title":"J Clin Gastroenterol"},{"key":"2024092815371502500_bib7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF02258458","article-title":"Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas","volume":"18","author":"Becker","year":"1991","journal-title":"Eur J Nucl Med"},{"key":"2024092815371502500_bib8","first-page":"649","article-title":"Evaluation of somatostatin receptors in human cancer","volume":"103","author":"Panter","year":"1991","journal-title":"Wien Klin Wochenschr"},{"key":"2024092815371502500_bib9","first-page":"1078","article-title":"Vasoactive intestinal polypeptide, neurotensin, substance P, gastrin-releasing peptide, calcitonin, calcitonin gene-related peptide, and somatostatinlike immunoreactivities in human parathyroid glands","volume":"110","author":"Weber","year":"1991","journal-title":"Surgery"},{"key":"2024092815371502500_bib10","first-page":"232","article-title":"Erfolgreiched Behandlung von Kopfschmerzen und Hypercalc\u00e4mie bei Akromegalie mit SMS 221\u2013995","volume":"68","author":"Jaspers","year":"1990","journal-title":"Klin Wochenschr"},{"key":"2024092815371502500_bib11","first-page":"S187","article-title":"Octreotide, a somatostatin analog, reduces urinary calcium excretion in children","volume":"5","author":"Palmieri","year":"1990","journal-title":"J Bone Miner Res"},{"key":"2024092815371502500_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/00365529209165429","article-title":"Gallbladder function in acromegalic patients taking long-term octreotide; evidence by rebound hypermotility on cessation of treatment","volume":"27","author":"Rhodes","year":"1992","journal-title":"Scand J Gastroenterol"}],"container-title":["Journal of British Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.1800810819","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/81\/8\/1141\/59413487\/bjs1800810819.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/81\/8\/1141\/59413487\/bjs1800810819.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:37:59Z","timestamp":1727537879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/81\/8\/1141\/6165714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,8,1]]},"references-count":12,"journal-issue":{"issue":"8","published-online":{"date-parts":[[1994,8,1]]},"published-print":{"date-parts":[[1994,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.1800810819","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"type":"print","value":"0007-1323"},{"type":"electronic","value":"1365-2168"}],"subject":[],"published-other":{"date-parts":[[1994,8]]},"published":{"date-parts":[[1994,8,1]]}}}